TRVI News and Press, Trevi Therapeutics Inc. From 11/12/23

2023-11-12 05:46:03 ET Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Conference Call November 09, 2023, 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Off...

2023-11-09 16:28:37 ET More on Trevi Therapeutics Seeking Alpha’s Quant Rating on Trevi Therapeutics Historical earnings data for Trevi Therapeutics Financial information for Trevi Therapeutics For further details see: Trevi Therapeutics GAAP EPS o...

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough (RCC) patients and expect topline data in the second half of 2024 Expect to initiate Phase ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Trevi Therapeutics Inc. (TRVI) is expected to report $-0.09 for Q3 2023

Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough PR Newswire Expect to enroll 60 subjects across a broad range of cough frequencies RIVER topline data expected in the second half of 2024 ...

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023 PR Newswire Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn. , Nov. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. ...

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis PR Newswire Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over ...

Trevi Therapeutics to Participate in Upcoming September Events PR Newswire NEW HAVEN, Conn. , Sept. 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio!...

2023-08-10 22:49:14 ET Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Conference Call August 10, 2023, 04:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants ...